An anticancer C-Kit kinase inhibitor is reengineered to make it more active and less cardiotoxic.
Fernández A, Sanguino A, Peng Z, Ozturk E, Chen J, Crespo A, Wulf S, Shavrin A, Qin C, Ma J, Trent J, Lin Y, Han HD, Mangala LS, Bankson JA, Gelovani J, Samarel A, Bornmann W, Sood AK, Lopez-Berestein G.
Fernández A, et al.
J Clin Invest. 2007 Dec;117(12):4044-54. doi: 10.1172/JCI32373.
J Clin Invest. 2007.
PMID: 18060038
Free PMC article.